Company Profile
Inhibrx Stock Price, News & Catalysts
- Ticker:
- INBX
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
104.73 USD (+2.91%)
Close
Last updated: September 17, 2026
1.37B USD
Market cap
Why the stock is moving
As of Sep 17, 2026, INBX closed up 2.91% at $104.73. No new same-company headline was identified in the current news window.
Company overview
Protein-Engineering Company
Inhibrx Biosciences develops multivalent biologics using protein-engineering platforms designed around the specific signaling requirements of complex therapeutic targets.
Ozekibart
Ozekibart, formerly INBRX-109, is a tetravalent DR5 agonist under FDA review for conventional chondrosarcoma. Additional development combines the candidate with standard regimens in colorectal cancer.
INBRX-106
INBRX-106 is a multivalent OX40 agonist intended to enhance antitumor immune activation. A randomized Phase 2 study combines it with pembrolizumab in head-and-neck squamous-cell carcinoma.
Dual Oncology Franchise
The company's near-term strategy combines a registration-stage rare-cancer program with broader combination development in colorectal and head-and-neck cancers.
Future catalysts
- Progression-free-survival data from the randomized Phase 2 INBRX-106 study in the third quarter of 2026.
- FDA meeting on ozekibart development in colorectal cancer in the fourth quarter of 2026.
- Interim data from the ozekibart colorectal-cancer cohorts in the first quarter of 2027.
- FDA action on the ozekibart BLA by the April 14, 2027 PDUFA goal date.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Inhibrx (INBX)?
Inhibrx (INBX) most recently closed at 104.73 USD, a +2.91% move versus the previous session.
What is the market cap of Inhibrx (INBX)?
Inhibrx currently has a market capitalization of 1.37B USD on BioPharmSignal.
What does Inhibrx do?
Protein-Engineering Company Inhibrx Biosciences develops multivalent biologics using protein-engineering platforms designed around the specific signaling requirements of complex therapeutic targets. Ozekibart Ozekibart, formerly INBRX-109, is a tetravalent DR5 agonist under FDA review for conventional chondrosarcoma. Additional development combines the...
On which exchange is INBX stock listed?
Inhibrx (INBX) is associated with NASDAQ, United States, Biopharma.
What is INBRX-109?
Ozekibart Ozekibart, formerly INBRX-109, is a tetravalent DR5 agonist under FDA review for conventional chondrosarcoma.
Which conditions is Inhibrx targeting with INBRX-109?
Inhibrx is associated with oncology, cancer therapeutics based on its company overview and current catalyst commentary.
How does Inhibrx describe recent progress with INBRX-109?
Progression-free-survival data from the randomized Phase 2 INBRX-106 study in the third quarter of 2026. FDA meeting on ozekibart development in colorectal cancer in the fourth quarter of 2026. Interim data from the ozekibart colorectal-cancer cohorts in the first quarter of 2027. FDA action on the ozekibart BLA by the April 14, 2027 PDUFA goal date.
What is INBRX-106?
INBRX-106 INBRX-106 is a multivalent OX40 agonist intended to enhance antitumor immune activation.